Published in Biomed Res Int on July 31, 2013
Xenobiotic transporter expression along the male genital tract. Reprod Toxicol (2014) 0.78
Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment. BMC Cancer (2016) 0.78
The role of genetic factors and kidney and liver function in glycemic control in type 2 diabetes patients on long-term metformin and sulphonylurea cotreatment. Biomed Res Int (2014) 0.77
The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma. Oncotarget (2017) 0.76
Impact of ATM and SLC22A1 Polymorphisms on Therapeutic Response to Metformin in Iranian Diabetic Patients. Int J Mol Cell Med (2016) 0.75
Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs. Pharmacogenomics J (2016) 0.75
Fine Mapping and Functional Analysis Reveal a Role of SLC22A1 in Acylcarnitine Transport. Am J Hum Genet (2017) 0.75
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science (1983) 9.41
Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc Natl Acad Sci U S A (2003) 5.77
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest (2007) 4.47
Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res (2007) 3.72
Active transport of imatinib into and out of cells: implications for drug resistance. Blood (2004) 3.52
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol (2012) 3.04
Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology (2009) 2.59
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol (2005) 2.56
Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res (2006) 2.37
Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther (2002) 2.36
Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab (2009) 2.17
Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci U S A (2003) 2.03
The SLC22 drug transporter family. Pflugers Arch (2003) 1.95
Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol (1997) 1.91
Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol (2006) 1.80
Polyamine catabolism and disease. Biochem J (2009) 1.79
Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther (2003) 1.78
Drug excretion mediated by a new prototype of polyspecific transporter. Nature (1994) 1.77
Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat Neurosci (1998) 1.70
Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol (1997) 1.66
Individual PKC-phosphorylation sites in organic cation transporter 1 determine substrate selectivity and transport regulation. J Am Soc Nephrol (2005) 1.65
Amino acids critical for substrate affinity of rat organic cation transporter 1 line the substrate binding region in a model derived from the tertiary structure of lactose permease. Mol Pharmacol (2005) 1.63
Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol (2005) 1.62
Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol (2002) 1.58
Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J (2009) 1.58
Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J Hum Genet (2006) 1.48
Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther (2007) 1.47
Cloning of the mouse and human solute carrier 22a3 (Slc22a3/SLC22A3) identifies a conserved cluster of three organic cation transporters on mouse chromosome 17 and human 6q26-q27. Genomics (1999) 1.45
The SLC22 family with transporters of organic cations, anions and zwitterions. Mol Aspects Med (2013) 1.45
Organic cation transporters in intestine, kidney, liver, and brain. Annu Rev Physiol (1998) 1.44
Polyspecific organic cation transporters: their functions and interactions with drugs. Trends Pharmacol Sci (2004) 1.36
Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Mol Cancer Ther (2011) 1.35
Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics (2002) 1.34
Transport of paraquat by human organic cation transporters and multidrug and toxic compound extrusion family. J Pharmacol Exp Ther (2007) 1.33
Role of organic cation transporters in the renal handling of therapeutic agents and xenobiotics. Toxicol Appl Pharmacol (2005) 1.33
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. J Med Chem (2008) 1.32
Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther (2002) 1.31
hOCT 1 and resistance to imatinib. Blood (2005) 1.28
The molecular pharmacology of organic anion transporters: from DNA to FDA? Mol Pharmacol (2004) 1.25
Structure of renal organic anion and cation transporters. Am J Physiol Renal Physiol (2000) 1.24
Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol (1998) 1.21
Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res (2009) 1.16
ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model. Mol Cancer Ther (2003) 1.12
Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab Dispos (2008) 1.12
Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther (1998) 1.11
Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions. Biochem Biophys Res Commun (2004) 1.09
NBD-TMA: a novel fluorescent substrate of the peritubular organic cation transporter of renal proximal tubules. Pflugers Arch (2000) 1.09
Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients. Pharmacogenet Genomics (2012) 1.07
Kinetic and selectivity differences between rodent, rabbit, and human organic cation transporters (OCT1). J Pharmacol Exp Ther (2000) 1.06
DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma. Genome Med (2011) 1.05
Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum(II) and cis-diammine-bisursodeoxycholate-platinum(II) toward liver cells. Mol Pharmacol (2002) 1.03
Transport of dicationic drugs pentamidine and furamidine by human organic cation transporters. Drug Metab Dispos (2008) 1.01
Effects of OCT1 polymorphisms on the cellular uptake, plasma concentrations and efficacy of the 5-HT(3) antagonists tropisetron and ondansetron. Pharmacogenomics J (2010) 1.01
Alkali cation binding and permeation in the rat organic cation transporter rOCT2. J Biol Chem (2005) 1.00
The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. Blood (2012) 0.99
Membrane localization of the electrogenic cation transporter rOCT1 in rat liver. Biochem Biophys Res Commun (1998) 0.99
Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther (2002) 0.98
Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. Hepatology (2013) 0.98
Regulation of organic cation transport. Pflugers Arch (2004) 0.98
Substrate recognition and translocation by polyspecific organic cation transporters. Biol Chem (2011) 0.97
Molecular cloning, functional characterization and genomic organization of four alternatively spliced isoforms of the human organic cation transporter 1 (hOCT1/SLC22A1). Ann Hum Genet (1999) 0.97
Genetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function. J Pharmacol Exp Ther (2010) 0.96
Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue. Mol Cancer Ther (2010) 0.96
In vitro evidence for the role of OATP and OCT uptake transporters in drug-drug interactions. Expert Opin Drug Metab Toxicol (2009) 0.96
Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1). Naunyn Schmiedebergs Arch Pharmacol (2007) 0.95
The affinity of the organic cation transporter rOCT1 is increased by protein kinase C-dependent phosphorylation. J Am Soc Nephrol (2000) 0.95
Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol. Clin Pharmacol Ther (2011) 0.95
No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors. Mol Pharm (2012) 0.93
Polyamine transport by the polyspecific organic cation transporters OCT1, OCT2, and OCT3. Mol Pharm (2013) 0.92
Human organic cation transporter 1 is expressed in lymphoma cells and increases susceptibility to irinotecan and paclitaxel. J Pharmacol Exp Ther (2011) 0.92
Regulation of the human organic cation transporter hOCT1. J Cell Physiol (2004) 0.92
Seven novel single nucleotide polymorphisms in the human SLC22A1 gene encoding organic cation transporter 1 (OCT1). Drug Metab Pharmacokinet (2004) 0.91
Studies on intestinal absorption of sulpiride (2): transepithelial transport of sulpiride across the human intestinal cell line Caco-2. Biol Pharm Bull (2002) 0.91
Lamotrigine is a substrate for OCT1 in brain endothelial cells. Biochem Pharmacol (2011) 0.91
Agmatine is efficiently transported by non-neuronal monoamine transporters extraneuronal monoamine transporter (EMT) and organic cation transporter 2 (OCT2). J Pharmacol Exp Ther (2003) 0.90
Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance. BMC Cancer (2012) 0.89
The human organic cation transporter-1 gene is transactivated by hepatocyte nuclear factor-4alpha. J Pharmacol Exp Ther (2006) 0.89
Sorafenib hepatobiliary disposition: mechanisms of hepatic uptake and disposition of generated metabolites. Drug Metab Dispos (2013) 0.89
Uptake of mIBG and catecholamines in noradrenaline- and organic cation transporter-expressing cells: potential use of corticosterone for a preferred uptake in neuroblastoma- and pheochromocytoma cells. Nucl Med Biol (2009) 0.88
Catalog of 238 variations among six human genes encoding solute carriers ( hSLCs) in the Japanese population. J Hum Genet (2002) 0.87
The two human organic cation transporter genes SLC22A1 and SLC22A2 are located on chromosome 6q26. Cytogenet Cell Genet (1997) 0.86
Human organic cation transporters 1 (SLC22A1), 2 (SLC22A2), and 3 (SLC22A3) as disposition pathways for fluoroquinolone antimicrobials. Antimicrob Agents Chemother (2013) 0.86
Pretherapeutic expression of the hOCT1 gene predicts a complete molecular response to imatinib mesylate in chronic-phase chronic myeloid leukemia. Acta Haematol (2012) 0.86
Genetic variants in genes involved in mechanisms of chemoresistance to anticancer drugs. Curr Cancer Drug Targets (2012) 0.86
Characterization of a transport and detoxification pathway for the antitumour drug bleomycin in Saccharomyces cerevisiae. Biochem J (2004) 0.85
Transport of guanidine compounds by human organic cation transporters, hOCT1 and hOCT2. Biochem Pharmacol (2009) 0.85
OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users. Neurogenetics (2010) 0.85
Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol (2005) 0.83
Cloning and functional expression of a mouse liver organic cation transporter. Hepatology (1999) 0.83
Carrier-mediated transport in the hepatic distribution and elimination of drugs, with special reference to the category of organic cations. J Pharmacokinet Biopharm (1990) 0.83
Functional involvement of organic cation transporter1 (OCT1/Oct1) in the hepatic uptake of organic cations in humans and rats. Xenobiotica (2007) 0.83
Guanidino compounds in uraemic dialysed patients. Clin Chim Acta (1986) 0.83
Comparison of "type I" and "type II" organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther (2001) 0.83
Cell membrane transport of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the liver and systemic bioavailability. Biochem Biophys Res Commun (2001) 0.83
Carrier-mediated uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small-molecule survivin suppressant, into human solid tumor and lymphoma cells. Drug Metab Dispos (2008) 0.83
Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular carcinoma. Int J Oncol (2013) 0.81
Role of organic cation transporter 1, OCT1 in the pharmacokinetics and toxicity of cis-diammine(pyridine)chloroplatinum(II) and oxaliplatin in mice. Pharm Res (2010) 0.81
Characterization of human OCT1-mediated transport of DAPI as a fluorescent probe substrate. J Pharm Sci (2011) 0.81
Organic cation transporters: physiology, toxicology and special focus on ethidium as a novel substrate. Curr Drug Metab (2009) 0.81
Bile-acid-induced cell injury and protection. World J Gastroenterol (2009) 2.06
The antiviral activities of artemisinin and artesunate. Clin Infect Dis (2008) 1.55
Bile acids: chemistry, physiology, and pathophysiology. World J Gastroenterol (2009) 1.51
Effect of artemisinin/artesunate as inhibitors of hepatitis B virus production in an "in vitro" replicative system. Antiviral Res (2005) 1.10
Maternal cholestasis during pregnancy programs metabolic disease in offspring. J Clin Invest (2013) 1.10
Antiviral effect of artemisinin from Artemisia annua against a model member of the Flaviviridae family, the bovine viral diarrhoea virus (BVDV). Planta Med (2006) 1.09
Inhibition of Na+-taurocholate Co-transporting polypeptide-mediated bile acid transport by cholestatic sulfated progesterone metabolites. J Biol Chem (2010) 1.08
Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin. Biochem J (2003) 1.07
Potential role of trans-inhibition of the bile salt export pump by progesterone metabolites in the etiopathogenesis of intrahepatic cholestasis of pregnancy. J Hepatol (2005) 1.07
Matrigel-embedded 3D culture of Huh-7 cells as a hepatocyte-like polarized system to study hepatitis C virus cycle. Virology (2012) 1.06
Expression of transporters potentially involved in the targeting of cytostatic bile acid derivatives to colon cancer and polyps. Biochem Pharmacol (2006) 1.03
Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum(II) and cis-diammine-bisursodeoxycholate-platinum(II) toward liver cells. Mol Pharmacol (2002) 1.03
Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer. Drug Metab Rev (2012) 1.00
Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. Hepatology (2013) 0.98
Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta. Mol Pharmacol (2011) 0.98
OATP8/1B3-mediated cotransport of bile acids and glutathione: an export pathway for organic anions from hepatocytes? J Biol Chem (2006) 0.97
Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition. Biochem Pharmacol (2013) 0.92
Activation of the nuclear receptor FXR enhances hepatocyte chemoprotection and liver tumor chemoresistance against genotoxic compounds. Biochim Biophys Acta (2013) 0.91
Molecular pathogenesis of intrahepatic cholestasis of pregnancy. Expert Rev Mol Med (2008) 0.88
Relationship between asymptomatic hypercholanaemia of pregnancy and progesterone metabolism. Clin Sci (Lond) (2002) 0.88
A homozygous nonsense mutation (c.214C->A) in the biliverdin reductase alpha gene (BLVRA) results in accumulation of biliverdin during episodes of cholestasis. J Med Genet (2011) 0.87
Oxidative stress and apoptosis in fetal rat liver induced by maternal cholestasis. Protective effect of ursodeoxycholic acid. J Hepatol (2005) 0.86
Molecular bases of the fetal liver-placenta-maternal liver excretory pathway for cholephilic compounds. Liver Int (2008) 0.86
Further characterization of the electrogenicity and pH sensitivity of the human organic anion-transporting polypeptides OATP1B1 and OATP1B3. Mol Pharmacol (2010) 0.85
Excretion of biliary compounds during intrauterine life. World J Gastroenterol (2009) 0.85
Nitric oxide mimics transcriptional and post-translational regulation during α-tocopherol cytoprotection against glycochenodeoxycholate-induced cell death in hepatocytes. J Hepatol (2010) 0.85
Novel cationic and neutral glycocholic acid and polyamine conjugates able to inhibit transporters involved in hepatic and intestinal bile acid uptake. Bioorg Med Chem (2007) 0.83
Changes in the pool of bile acids in hepatocyte nuclei during rat liver regeneration. J Hepatol (2002) 0.82
Novel artemisinin derivatives with potential usefulness against liver/colon cancer and viral hepatitis. Bioorg Med Chem (2013) 0.82
Usefulness of combined measurement of serum bile acids and ferritin as additional prognostic markers to predict failure to reach sustained response to antiviral treatment in chronic hepatitis C. J Gastroenterol Hepatol (2005) 0.81
Changes in the expression of genes related to bile acid synthesis and transport by the rat liver during hepatocarcinogenesis. Clin Sci (Lond) (2005) 0.81
Ontogenic development-associated changes in the expression of genes involved in rat bile acid homeostasis. J Lipid Res (2007) 0.81
Molecular bases of the excretion of fetal bile acids and pigments through the fetal liver-placenta-maternal liver pathway. Ann Hepatol (2005) 0.80
Effect of ursodeoxycholic acid treatment on the altered progesterone and bile acid homeostasis in the mother-placenta-foetus trio during cholestasis of pregnancy. Br J Clin Pharmacol (2015) 0.80
Protective effect of bile acid derivatives in phalloidin-induced rat liver toxicity. Toxicol Appl Pharmacol (2009) 0.80
Cisplatin-induced chemoresistance in colon cancer cells involves FXR-dependent and FXR-independent up-regulation of ABC proteins. Mol Pharm (2012) 0.80
Inhibition of the intestinal absorption of bile acids using cationic derivatives: mechanism and repercussions. Biochem Pharmacol (2006) 0.80
Role of macrophages in bile acid-induced inflammatory response of fetal lung during maternal cholestasis. J Mol Med (Berl) (2013) 0.80
Cocarcinogenic effects of intrahepatic bile acid accumulation in cholangiocarcinoma development. Mol Cancer Res (2013) 0.79
Alterations in Enterohepatic Fgf15 Signaling and Changes in Bile Acid Composition Depend on Localization of Murine Intestinal Inflammation. Inflamm Bowel Dis (2016) 0.78
Bile Acids in Physiology, Pathology and Pharmacology. Curr Drug Metab (2015) 0.78
Maternal ethanol consumption during pregnancy enhances bile acid-induced oxidative stress and apoptosis in fetal rat liver. Toxicology (2006) 0.78
Long-term effect of treating pregnant rats with ursodeoxycholic acid on the congenital impairment of bile secretion induced in the pups by maternal cholestasis. J Pharmacol Exp Ther (2004) 0.78
Transient changes in the expression pattern of key enzymes for bile acid synthesis during rat liver regeneration. Biochim Biophys Acta (2005) 0.78
Lack of Abcc3 expression impairs bile-acid induced liver growth and delays hepatic regeneration after partial hepatectomy in mice. J Hepatol (2011) 0.78
Importance and limitations of chemotherapy among the available treatments for gastrointestinal tumours. Anticancer Agents Med Chem (2009) 0.77
Acetaminophen-induced stimulation of MDR1 expression and activity in rat intestine and in LS 174T human intestinal cell line. Biochem Pharmacol (2010) 0.77
Cytosol-nucleus traffic and colocalization with FXR of conjugated bile acids in rat hepatocytes. Am J Physiol Gastrointest Liver Physiol (2008) 0.77
A review on the molecular mechanisms involved in the placental barrier for drugs. Curr Drug Deliv (2004) 0.77
Hepatic expression of sodium-dependent vitamin C transporters: ontogeny, subtissular distribution and effect of chronic liver diseases. Br J Nutr (2011) 0.77
Sensitivity of bile acid transport by organic anion-transporting polypeptides to intracellular pH. Biochim Biophys Acta (2003) 0.77
Cytoprotective properties of rifampicin are related to the regulation of detoxification system and bile acid transporter expression during hepatocellular injury induced by hydrophobic bile acids. J Hepatobiliary Pancreat Sci (2011) 0.77
The expression of genes involved in hepatocellular carcinoma chemoresistance is affected by mitochondrial genome depletion. Mol Pharm (2014) 0.76
Expression, localization, and inducibility by bile acids of hepatobiliary transporters in the new polarized rat hepatic cell lines, Can 3-1 and Can 10. Cell Tissue Res (2007) 0.76
Multiple protective effects of melatonin against maternal cholestasis-induced oxidative stress and apoptosis in the rat fetal liver-placenta-maternal liver trio. J Pineal Res (2007) 0.76
Hepatobiliary transporters in the pharmacology and toxicology of anticancer drugs. Front Biosci (Landmark Ed) (2009) 0.76
Usefulness of liposomes loaded with cytostatic bile acid derivatives to circumvent chemotherapy resistance of enterohepatic tumors. Mol Pharmacol (2003) 0.76
ABCC2 is involved in the hepatocyte perinuclear barrier for small organic compounds. Biochem Pharmacol (2012) 0.76
In vitro inhibition of OATP-mediated uptake of phalloidin using bile acid derivatives. Toxicol Appl Pharmacol (2009) 0.76
Role of vitamin C transporters and biliverdin reductase in the dual pro-oxidant and anti-oxidant effect of biliary compounds on the placental-fetal unit in cholestasis during pregnancy. Toxicol Appl Pharmacol (2008) 0.76
Novel bile acid derivatives (BANBs) with cytostatic activity obtained by conjugation of their side chain with nitrogenated bases. Biochem Pharmacol (2006) 0.75
Proapoptotic effect on normal and tumor intestinal cells of cytostatic drugs with enterohepatic organotropism. J Pharmacol Exp Ther (2005) 0.75
Relationship between tumor cell load and sensitivity to the cytostatic effect of two novel platinum-bile acid complexes, Bamet-D3 and Bamet-UD2. J Drug Target (2002) 0.75
Liver metabolic/oxidative stress induces hepatic and extrahepatic changes in the expression of the vitamin C transporters SVCT1 and SVCT2. Eur J Nutr (2013) 0.75
Physiological characteristics of allo-cholic acid. J Lipid Res (2003) 0.75
Characterization of WIF-B9/R cells as an in vitro model with hepatocyte-like polarity and enhanced expression of canalicular ABC transporters involved in phase III of hepatic detoxification. Toxicology (2007) 0.75
Excretion of fetal biliverdin by the rat placenta-maternal liver tandem. Am J Physiol Regul Integr Comp Physiol (2005) 0.75
How we have learned about the complexity of physiology, pathobiology and pharmacology of bile acids and biliary secretion. World J Gastroenterol (2008) 0.75
Effect of maternal obstructive cholestasis during pregnancy on the biliary transport of horseradish peroxidase in the rat offspring. Clin Sci (Lond) (2003) 0.75
Evidence for dual effects of DNA-reactive bile acid derivatives (Bamets) on hepatitis B virus life cycle in an in vitro replicative system. Antivir Chem Chemother (2002) 0.75
Bile Acids in Polycystic Liver Diseases: Triggers of Disease Progression and Potential Solution for Treatment. Dig Dis (2017) 0.75